<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875133</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0088</org_study_id>
    <nct_id>NCT01875133</nct_id>
  </id_info>
  <brief_title>Patients With Chronic Obstructive Pulmonary Disease At Altitude</brief_title>
  <official_title>Effect of Altitude on Exercise Performance of Patients With Chronic Obstructive Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of a stay at moderate altitude on
      exercise performance of patients with chronic obstructive lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with moderate to severe COPD living below 800 m, will be recruited to participate
      in a randomized cross-over field trial evaluating the hypothesis that exercise capacity
      during a 4 day sojourn at moderate altitude is reduced in comparison to low altitude.
      Outcomes will be assessed during 2 days in Zurich (490 m, low altitude baseline), 2 days at
      Davos Clavadel (1650 m), and 2 days at Davos Jakobshorn (2590 m). The main outcome is the 6
      minute walk distance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in exercise performance from baseline measured at 490 m</measure>
    <time_frame>Change in 6 min walk distance from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 min walk distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise performance from baseline measured at 490 m</measure>
    <time_frame>Change in 6 min walk distance from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 min walk distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function from baseline measured at 490 m</measure>
    <time_frame>Change in pulmonary function from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>lung volumes by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function from baseline measured at 490 m</measure>
    <time_frame>Change in pulmonary function from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>lung volumes by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial blood gases from baseline measured at 490 m</measure>
    <time_frame>Change in arterial blood gases from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Arterial blood gas analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial blood gases from baseline measured at 490 m</measure>
    <time_frame>Change in arterial blood gases from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Arterial blood gas analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived exertion from baseline measured at 490 m</measure>
    <time_frame>Change in perceived exertion from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Borg CR10 scale at end of 6 min walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived exertion from baseline measured at 490 m</measure>
    <time_frame>Change in perceived exertion from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Borg CR10 scale at end of 6 min walk</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>A: low-intermediate-high altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence A, 490-1630-2590m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: low-high-intermediate altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence B, 490-2590-1630 m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: intermediate-high-low altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence C, 1630-2590-490 m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: high-intermediate-low altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence D, 2590-1630-490 m</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>altitude exposure</intervention_name>
    <description>stay at different altitudes: 490, 1630, 2590 m</description>
    <arm_group_label>A: low-intermediate-high altitude</arm_group_label>
    <arm_group_label>B: low-high-intermediate altitude</arm_group_label>
    <arm_group_label>C: intermediate-high-low altitude</arm_group_label>
    <arm_group_label>D: high-intermediate-low altitude</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic obstructive pulmonary disease (COPD), GOLD grade 2-3

          -  residents at low altitude (&lt;800 m)

        Exclusion Criteria:

          -  Unstable condition, COPD exacerbation

          -  Mild (GOLD 1) or very severe COPD (GOLD 4)

          -  requirement for oxygen therapy at low altitude residence

          -  hypoventilation

          -  pulmonary hypertension

          -  more than mild or unstable cardiovascular disease

          -  use of drugs that affect respiratory center drive

          -  internal, neurologic or psychiatric disease that interfere with protocol compliance
             including current heavy smoking (&gt;20 cigarettes per day), inability to perform 6 min
             walk test.

          -  previous intolerance to moderate altitude (&lt;2600m).

          -  Exposure to altitudes &gt;1500m for &gt;2 days within the last 4 weeks before the study.

          -  Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsogyal D Latshang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad E Bloch, MD</last_name>
    <phone>+41 44 255 3828</phone>
    <email>konrad.bloch@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tsogyal D Latshang, MD</last_name>
    <phone>+41 44 255 3828</phone>
    <email>tsogyal.latshagn@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Pulmonary Division</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad E Bloch, MD</last_name>
      <phone>+41 44 255 3828</phone>
      <email>konrad.bloch@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tsogyal D Latshang, MD</last_name>
      <phone>+41 44 255 3828</phone>
      <email>tsogyal.latshang@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Konrad E Bloch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 6, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>airway disease</keyword>
  <keyword>bronchitis</keyword>
  <keyword>emphysema</keyword>
  <keyword>lung</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
